RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prevalence of rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in Middle Eastern colorectal cancer (CRC) patients was reviewed. KRAS mutations were most common, showing regional variations important for targeted therapies.
Area Of Science
- Oncology
- Genetics
- Epidemiology
Background
- Colorectal cancer (CRC) is a significant health concern globally.
- Understanding the genetic landscape of CRC, specifically RAS and BRAF mutations, is crucial for effective treatment.
- Geographical variations in mutation prevalence can impact patient outcomes and therapeutic strategies.
Purpose Of The Study
- To investigate the prevalence and spectrum of rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in colorectal cancer (CRC) patients in the Middle East.
- To explore the association between these mutations, geographical location, and clinicopathological features.
- To provide insights into regional differences in CRC genetic profiles.
Main Methods
- Systematic literature review adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework.
- Comprehensive search of multiple electronic databases including PubMed, Science Direct, Web of Science, Scopus, and Google Scholar.
- Analysis of data from 19 eligible studies encompassing 2960 CRC patients.
Main Results
- RAS mutation prevalence was 38.1% in the studied Middle Eastern CRC cohort.
- Kirsten RAS Viral Oncogene Homolog (KRAS) mutations were most frequent (37.1%), with G12D being the most common specific mutation.
- Neuroblastoma RAS Viral Oncogene Homolog (NRAS) mutations occurred in 3.3%, and BRAF mutations in 2.6%, with V600E being the most common BRAF alteration.
Conclusions
- RAS and BRAF mutation patterns in CRC patients show significant ethnic and geographical variations.
- This study highlights a higher prevalence of KRAS mutations in Middle Eastern CRC patients compared to other regions.
- Understanding these regional mutation differences is vital for personalized treatment planning and developing targeted therapies for CRC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...